WELLBUTRIN SR

Compare WELLBUTRIN SR  to:
Compare
Compare

Generic Name for WELLBUTRIN SR

Bupropion HCl 100mg, 150mg, 200mg; sust-rel tabs.

Legal Classification:

Rx

Pharmacological Class for WELLBUTRIN SR

Aminoketone.

Manufacturer of WELLBUTRIN SR

GlaxoSmithKline Pharmaceuticals

Indications for WELLBUTRIN SR

Depression.

Adult dose for WELLBUTRIN SR

Swallow whole. Avoid bedtime dosing. ≥18yrs: initially 150mg once daily in the AM for at least 3 days; if tolerated, increase to 150mg twice daily at least 8 hrs apart. May increase after several weeks to max 200mg twice daily at least 8 hrs apart. Severe hepatic cirrhosis: max 100mg/day or 150mg every other day. Mild-moderate hepatic cirrhosis, or renal impairment: consider reduced dose and/or dose frequency.

Children's dosing for WELLBUTRIN SR

<18yrs: not recommended.

Also:

Contraindications for WELLBUTRIN SR

Seizure disorders. Bulimia. Anorexia nervosa. Within 14 days of MAOIs. Abrupt withdrawal of sedatives or alcohol. Other forms of bupropion (eg, Zyban).

Precautions for WELLBUTRIN SR

History or risk of seizures; discontinue if seizure occurs: do not restart. Hepatic or renal impairment (monitor closely). Depression: clinical worsening or suicidal risk (monitor). Bipolar disorder. Psychosis. Unstable heart disease. CHF. Recent MI. Maintain at lowest effective dose. Write ℞ for smallest practical amount. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for WELLBUTRIN SR

See Contraindications. Avoid alcohol. Levodopa, amantadine may increase toxicity. Caution with drugs that lower seizure threshold (eg, quinolones, theophylline, antidiabetics, anorectics, CNS stimulants, systemic steroids, antidepressants, antipsychotics) or factors that lower seizure threshold (eg, opiate or cocaine addiction, excessive use of alcohol or sedatives). Caution with drugs metabolized by CYP2B6 (eg, orphenadrine, cyclophosphamide) or CYP2D6 including tricyclic antidepressants, SSRIs (eg, paroxetine, fluoxetine, sertraline), antipsychotics (eg, haloperidol, risperidone, thioridazine), β-blockers (eg, metoprolol), Class 1C antiarrhythmics (eg, propafenone, flecainide); consider dose reduction. May be affected by metabolic enzyme inducers (eg, carbamazepine, phenobarbital, phenytoin), or inhibitors (eg, cimetidine). Monitor for hypertension with nicotine replacement.

Adverse Reactions for WELLBUTRIN SR

CNS stimulation (eg, agitation, insomnia, seizures, tremor, dizziness), mania/hypomania, psychosis, weight change, dry mouth, headache, migraine, GI effects, edema, rash (rarely may be serious, eg, erythema multiforme, Stevens-Johnson syndrome), palpitations, urinary frequency, sweating, tinnitus, myalgia, hypertension.

How is WELLBUTRIN SR supplied?

XL tabs—30, 90
SR tabs—60
Immediate-rel tabs—100

Related Disease:

Depression

Related Resources

Oleptro approved for major depressive disorder (MDD)

February 03, 2010

The FDA has approved Oleptro (trazodone HCl extended-release tablets, from Labopharm), a once-daily formulation of trazodone, for the treatment of major depressive disorder (MDD) in adults.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Seroquel XR approved for adjunctive treatment of major depressive disorder (MDD)

December 07, 2009

Seroquel XR (quetiapine fumarate extended-release tablets, from AstraZeneca) has been approved by the FDA as adjunctive treatment to antidepressants in adults with major depressive disorder (MDD).

Zyprexa approved for schizophrenia and bipolar I disorder in adolescents

December 07, 2009

The FDA has approved Zyprexa (olanzapine, from Lilly) tablets for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents 13-17 years of age.

FDA warns of birth defects with valproate sodium, valproic acid, and divalproex sodium

December 03, 2009

The FDA has notified healthcare professionals and patients about the increased risk of neural tube defects and other major birth defects (eg, craniofacial defects and cardiovascular malformations) in babies exposed to valproate sodium and related products (valproic acid and divalproex sodium) during pregnancy.